Drug Evaluation Committee Results of Questionnaire on Electronic Provision of Information - Trend of companies participating in the Pharmaceutical Manufacturers Association of Japan (conducted in January 2023)

Pharmacovigilance Subcommittee

January 2024

With the VISION of "contributing to patient safety and security by establishing an ideal system for providing safety information from the viewpoints of patients and medical professionals and delivering necessary information," we are working to promote risk communication using DX. In January 2023, we conducted a survey of companies belonging to the PV Committee of the Pharmaceutical Manufacturers Association of Japan (PMAJ) to summarize the current status and issues regarding the provision of safety information using digital media to healthcare professionals, and to make recommendations for more appropriate provision of safety information and information dissemination.

Results of the survey (please click here first)

Results of Questionnaire on Electronic Provision of Information: Trends among companies participating in the Pharmaceutical Manufacturers Association of Japan (conducted in January 2023) (1,538KB)

Supplementary data

Results of the Questionnaire on Electronic Provision of Information - Trends in Pharmaceutical Manufacturers - (January 2023) Appendix 1: List of Questionnaire Questions (499KB)

Results of the Questionnaire on Electronic Provision of Information - Trends in the Pharmaceutical Manufacturers' Association of Japan (January 2023) Attachment 2: List of Answers to the Open-Ended Questionnaire (314KB)

Deliverables of the Drug Evaluation Committee Return to list of all deliverables

TOP